Efficacy of tofacitinib in patients with rheumatoid arthritis stratified by background methotrexate dose group View Full Text


Ontology type: schema:ScholarlyArticle      Open Access: True


Article Info

DATE

2016-10-12

AUTHORS

R Fleischmann, P J Mease, S Schwartzman, L-J Hwang, K Soma, C A Connell, L Takiya, E Bananis

ABSTRACT

Tofacitinib is an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis (RA). This post hoc analysis investigated the effect of methotrexate (MTX) dose on the efficacy of tofacitinib in patients with RA. ORAL Scan (NCT00847613) was a 2-year, randomized, Phase 3 trial evaluating tofacitinib in MTX-inadequate responder (IR) patients with RA. Patients received tofacitinib 5 or 10 mg twice daily (BID), or placebo, with low (≤12.5 mg/week), moderate (>12.5 to <17.5 mg/week), or high (≥17.5 mg/week) stable background MTX. Efficacy endpoints (at months 3 and 6) included American College of Rheumatology (ACR) 20/50/70 response rates, and mean change from baseline in Clinical Disease Activity Index (CDAI), Disease Activity Score in 28 joints (DAS28)-4(erythrocyte sedimentation rate [ESR]), Health Assessment Questionnaire-Disability Index (HAQ-DI), and modified Total Sharp score. 797 patients were treated with tofacitinib 5 mg BID (N = 321), tofacitinib 10 mg BID (N = 316), or placebo (N = 160); 242, 333, and 222 patients received low, moderate, and high MTX doses, respectively. At months 3 and 6, ACR20/50/70 response rates were greater for both tofacitinib doses vs placebo across all MTX doses. At month 3, mean changes from baseline in CDAI and HAQ-DI were significantly greater for both tofacitinib doses vs placebo, irrespective of MTX category; improvements were maintained at month 6. Both tofacitinib doses demonstrated improvements in DAS28-4(ESR), and less structural progression vs placebo, across MTX doses at month 6. Tofacitinib plus MTX showed greater clinical and radiographic efficacy than placebo in MTX-IR patients with RA, regardless of MTX dose. More... »

PAGES

15-24

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/s10067-016-3436-1

DOI

http://dx.doi.org/10.1007/s10067-016-3436-1

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1011836710

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/27734232


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1103", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Clinical Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Adult", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Antirheumatic Agents", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Arthritis, Rheumatoid", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Blood Sedimentation", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Disease Progression", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Double-Blind Method", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Drug Therapy, Combination", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Female", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Janus Kinases", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Male", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Methotrexate", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Middle Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Piperidines", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Pyrimidines", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Pyrroles", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Regression Analysis", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Surveys and Questionnaires", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Treatment Outcome", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Metroplex Clinical Research Center and University of Texas Southwestern Medical Center, Dallas, TX, USA.", 
          "id": "http://www.grid.ac/institutes/grid.267313.2", 
          "name": [
            "Metroplex Clinical Research Center and University of Texas Southwestern Medical Center, Dallas, TX, USA."
          ], 
          "type": "Organization"
        }, 
        "familyName": "Fleischmann", 
        "givenName": "R", 
        "id": "sg:person.01065106031.43", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01065106031.43"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Swedish Medical Center and University of Washington School of Medicine, Seattle, WA, USA.", 
          "id": "http://www.grid.ac/institutes/grid.34477.33", 
          "name": [
            "Swedish Medical Center and University of Washington School of Medicine, Seattle, WA, USA."
          ], 
          "type": "Organization"
        }, 
        "familyName": "Mease", 
        "givenName": "P J", 
        "id": "sg:person.012234527537.40", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.012234527537.40"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Hospital for Special Surgery, New York, NY, USA.", 
          "id": "http://www.grid.ac/institutes/grid.239915.5", 
          "name": [
            "Hospital for Special Surgery, New York, NY, USA."
          ], 
          "type": "Organization"
        }, 
        "familyName": "Schwartzman", 
        "givenName": "S", 
        "id": "sg:person.014133305773.18", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.014133305773.18"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Pfizer Inc, New York, NY, USA.", 
          "id": "http://www.grid.ac/institutes/grid.410513.2", 
          "name": [
            "Pfizer Inc, New York, NY, USA."
          ], 
          "type": "Organization"
        }, 
        "familyName": "Hwang", 
        "givenName": "L-J", 
        "id": "sg:person.01323573350.82", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01323573350.82"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Pfizer Inc, Groton, CT, USA.", 
          "id": "http://www.grid.ac/institutes/grid.410513.2", 
          "name": [
            "Pfizer Inc, Groton, CT, USA."
          ], 
          "type": "Organization"
        }, 
        "familyName": "Soma", 
        "givenName": "K", 
        "id": "sg:person.01011713026.12", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01011713026.12"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Pfizer Inc, Groton, CT, USA.", 
          "id": "http://www.grid.ac/institutes/grid.410513.2", 
          "name": [
            "Pfizer Inc, Groton, CT, USA."
          ], 
          "type": "Organization"
        }, 
        "familyName": "Connell", 
        "givenName": "C A", 
        "id": "sg:person.0614545245.28", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0614545245.28"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Pfizer Inc, Collegeville, PA, USA.", 
          "id": "http://www.grid.ac/institutes/grid.410513.2", 
          "name": [
            "Pfizer Inc, Collegeville, PA, USA."
          ], 
          "type": "Organization"
        }, 
        "familyName": "Takiya", 
        "givenName": "L", 
        "id": "sg:person.011262137261.94", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.011262137261.94"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Pfizer Inc, Collegeville, PA, USA. stratis.bananis@pfizer.com.", 
          "id": "http://www.grid.ac/institutes/grid.410513.2", 
          "name": [
            "Pfizer Inc, Collegeville, PA, USA. stratis.bananis@pfizer.com."
          ], 
          "type": "Organization"
        }, 
        "familyName": "Bananis", 
        "givenName": "E", 
        "id": "sg:person.01073167753.60", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01073167753.60"
        ], 
        "type": "Person"
      }
    ], 
    "datePublished": "2016-10-12", 
    "datePublishedReg": "2016-10-12", 
    "description": "Tofacitinib is an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis (RA). This post hoc analysis investigated the effect of methotrexate (MTX) dose on the efficacy of tofacitinib in patients with RA. ORAL Scan (NCT00847613) was a 2-year, randomized, Phase 3 trial evaluating tofacitinib in MTX-inadequate responder (IR) patients with RA. Patients received tofacitinib 5 or 10\u00a0mg twice daily (BID), or placebo, with low (\u226412.5\u00a0mg/week), moderate (>12.5 to <17.5\u00a0mg/week), or high (\u226517.5\u00a0mg/week) stable background MTX. Efficacy endpoints (at months 3 and 6) included American College of Rheumatology (ACR) 20/50/70 response rates, and mean change from baseline in Clinical Disease Activity Index (CDAI), Disease Activity Score in 28 joints (DAS28)-4(erythrocyte sedimentation rate [ESR]), Health Assessment Questionnaire-Disability Index (HAQ-DI), and modified Total Sharp score. 797 patients were treated with tofacitinib 5\u00a0mg BID (N\u00a0=\u00a0321), tofacitinib 10\u00a0mg BID (N\u00a0=\u00a0316), or placebo (N\u00a0=\u00a0160); 242, 333, and 222 patients received low, moderate, and high MTX doses, respectively. At months 3 and 6, ACR20/50/70 response rates were greater for both tofacitinib doses vs placebo across all MTX doses. At month 3, mean changes from baseline in CDAI and HAQ-DI were significantly greater for both tofacitinib doses vs placebo, irrespective of MTX category; improvements were maintained at month 6. Both tofacitinib doses demonstrated improvements in DAS28-4(ESR), and less structural progression vs placebo, across MTX doses at month 6. Tofacitinib plus MTX showed greater clinical and radiographic efficacy than placebo in MTX-IR patients with RA, regardless of MTX dose.", 
    "genre": "article", 
    "id": "sg:pub.10.1007/s10067-016-3436-1", 
    "inLanguage": "en", 
    "isAccessibleForFree": true, 
    "isPartOf": [
      {
        "id": "sg:journal.1093299", 
        "issn": [
          "0770-3198", 
          "1434-9949"
        ], 
        "name": "Clinical Rheumatology", 
        "publisher": "Springer Nature", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "1", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "36"
      }
    ], 
    "keywords": [
      "Health Assessment Questionnaire Disability Index", 
      "Clinical Disease Activity Index", 
      "efficacy of tofacitinib", 
      "rheumatoid arthritis", 
      "MTX doses", 
      "tofacitinib 5", 
      "month 3", 
      "month 6", 
      "response rate", 
      "MTX-inadequate responder patients", 
      "Rheumatology (ACR) 20/50/70 response rates", 
      "oral Janus kinase inhibitor", 
      "higher MTX doses", 
      "ACR20/50/70 response rates", 
      "MTX-IR patients", 
      "Disease Activity Index", 
      "Disease Activity Score", 
      "phase 3 trial", 
      "total Sharp score", 
      "Janus kinase inhibitor", 
      "background MTX", 
      "tofacitinib doses", 
      "radiographic efficacy", 
      "responder patients", 
      "MTX dose", 
      "efficacy endpoint", 
      "methotrexate dose", 
      "Sharp score", 
      "activity score", 
      "dose group", 
      "placebo", 
      "American College", 
      "patients", 
      "structural progression", 
      "tofacitinib", 
      "ORAL Scan", 
      "activity index", 
      "doses", 
      "kinase inhibitors", 
      "arthritis", 
      "efficacy", 
      "MTX", 
      "dose", 
      "baseline", 
      "scores", 
      "DAS28", 
      "trials", 
      "progression", 
      "endpoint", 
      "index", 
      "scans", 
      "treatment", 
      "inhibitors", 
      "rate", 
      "improvement", 
      "group", 
      "changes", 
      "joints", 
      "College", 
      "post", 
      "effect", 
      "bid", 
      "categories", 
      "analysis", 
      "high (\u226517.5\u00a0mg/week) stable background MTX", 
      "stable background MTX", 
      "Assessment Questionnaire-Disability Index", 
      "Questionnaire-Disability Index", 
      "MTX category", 
      "less structural progression", 
      "background methotrexate dose group", 
      "methotrexate dose group"
    ], 
    "name": "Efficacy of tofacitinib in patients with rheumatoid arthritis stratified by background methotrexate dose group", 
    "pagination": "15-24", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1011836710"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/s10067-016-3436-1"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "27734232"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1007/s10067-016-3436-1", 
      "https://app.dimensions.ai/details/publication/pub.1011836710"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2022-01-01T18:43", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20220101/entities/gbq_results/article/article_718.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://doi.org/10.1007/s10067-016-3436-1"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s10067-016-3436-1'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s10067-016-3436-1'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s10067-016-3436-1'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s10067-016-3436-1'


 

This table displays all metadata directly associated to this object as RDF triples.

278 TRIPLES      21 PREDICATES      118 URIs      110 LITERALS      27 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/s10067-016-3436-1 schema:about N00231aad54b140d0887602fe84360117
2 N030f1376377448e8ad63f0663b0e3bae
3 N0361341f98794be9ab080a5372ceffcc
4 N04a20bf21597425c9e643ae17df65f32
5 N0c3e46b75034427792556153e364e415
6 N109fe8fb05c741c3b41f972e8a1c2385
7 N191861c971ad49dcb7e3378671858b4e
8 N1b71cecea18643e9830a445e9ac6e48c
9 N287502c6477649229651b27097ff3e6c
10 N33bda90afd984c34a49338caa95a2bd1
11 N6e1425078cea4ad38b9d07b10175374c
12 N6ee1973da3a84ea898fd3d5102848a36
13 N85ae6e5156ca4d8686cb1b96f594dcb0
14 N9563d2922fca44529f0ceca9ecf2443b
15 N96e0aa0d03134a0d988bfa63615f994b
16 Na15b73d881774506a68235bf5a3c4482
17 Nb0c3f4e4a769407eb77279e526e7077e
18 Ne73abf2a84724c98b45207b3a5b264d1
19 Nf2c21df31075445da9eeedc91c37417a
20 Nf8f630ccdfbe4ccab5ca605dd80984e1
21 anzsrc-for:11
22 anzsrc-for:1103
23 schema:author N5a4002d88e994290afbd57ab870b2a49
24 schema:datePublished 2016-10-12
25 schema:datePublishedReg 2016-10-12
26 schema:description Tofacitinib is an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis (RA). This post hoc analysis investigated the effect of methotrexate (MTX) dose on the efficacy of tofacitinib in patients with RA. ORAL Scan (NCT00847613) was a 2-year, randomized, Phase 3 trial evaluating tofacitinib in MTX-inadequate responder (IR) patients with RA. Patients received tofacitinib 5 or 10 mg twice daily (BID), or placebo, with low (≤12.5 mg/week), moderate (>12.5 to <17.5 mg/week), or high (≥17.5 mg/week) stable background MTX. Efficacy endpoints (at months 3 and 6) included American College of Rheumatology (ACR) 20/50/70 response rates, and mean change from baseline in Clinical Disease Activity Index (CDAI), Disease Activity Score in 28 joints (DAS28)-4(erythrocyte sedimentation rate [ESR]), Health Assessment Questionnaire-Disability Index (HAQ-DI), and modified Total Sharp score. 797 patients were treated with tofacitinib 5 mg BID (N = 321), tofacitinib 10 mg BID (N = 316), or placebo (N = 160); 242, 333, and 222 patients received low, moderate, and high MTX doses, respectively. At months 3 and 6, ACR20/50/70 response rates were greater for both tofacitinib doses vs placebo across all MTX doses. At month 3, mean changes from baseline in CDAI and HAQ-DI were significantly greater for both tofacitinib doses vs placebo, irrespective of MTX category; improvements were maintained at month 6. Both tofacitinib doses demonstrated improvements in DAS28-4(ESR), and less structural progression vs placebo, across MTX doses at month 6. Tofacitinib plus MTX showed greater clinical and radiographic efficacy than placebo in MTX-IR patients with RA, regardless of MTX dose.
27 schema:genre article
28 schema:inLanguage en
29 schema:isAccessibleForFree true
30 schema:isPartOf N03fccb4a26194ebfa332831796fa6c55
31 Nb5034f1a75f242f8b7440188431cb8e2
32 sg:journal.1093299
33 schema:keywords ACR20/50/70 response rates
34 American College
35 Assessment Questionnaire-Disability Index
36 Clinical Disease Activity Index
37 College
38 DAS28
39 Disease Activity Index
40 Disease Activity Score
41 Health Assessment Questionnaire Disability Index
42 Janus kinase inhibitor
43 MTX
44 MTX category
45 MTX dose
46 MTX doses
47 MTX-IR patients
48 MTX-inadequate responder patients
49 ORAL Scan
50 Questionnaire-Disability Index
51 Rheumatology (ACR) 20/50/70 response rates
52 Sharp score
53 activity index
54 activity score
55 analysis
56 arthritis
57 background MTX
58 background methotrexate dose group
59 baseline
60 bid
61 categories
62 changes
63 dose
64 dose group
65 doses
66 effect
67 efficacy
68 efficacy endpoint
69 efficacy of tofacitinib
70 endpoint
71 group
72 high (≥17.5 mg/week) stable background MTX
73 higher MTX doses
74 improvement
75 index
76 inhibitors
77 joints
78 kinase inhibitors
79 less structural progression
80 methotrexate dose
81 methotrexate dose group
82 month 3
83 month 6
84 oral Janus kinase inhibitor
85 patients
86 phase 3 trial
87 placebo
88 post
89 progression
90 radiographic efficacy
91 rate
92 responder patients
93 response rate
94 rheumatoid arthritis
95 scans
96 scores
97 stable background MTX
98 structural progression
99 tofacitinib
100 tofacitinib 5
101 tofacitinib doses
102 total Sharp score
103 treatment
104 trials
105 schema:name Efficacy of tofacitinib in patients with rheumatoid arthritis stratified by background methotrexate dose group
106 schema:pagination 15-24
107 schema:productId N0c3ab250df324962a0f08861cc83c299
108 N7fa0c1777cff4c0f86d1368a416c4f6c
109 N82d0739072f449aba60a148f9d8b63ca
110 schema:sameAs https://app.dimensions.ai/details/publication/pub.1011836710
111 https://doi.org/10.1007/s10067-016-3436-1
112 schema:sdDatePublished 2022-01-01T18:43
113 schema:sdLicense https://scigraph.springernature.com/explorer/license/
114 schema:sdPublisher Ne5aa1ba4429749b2aafedd02f22eee94
115 schema:url https://doi.org/10.1007/s10067-016-3436-1
116 sgo:license sg:explorer/license/
117 sgo:sdDataset articles
118 rdf:type schema:ScholarlyArticle
119 N00231aad54b140d0887602fe84360117 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
120 schema:name Surveys and Questionnaires
121 rdf:type schema:DefinedTerm
122 N030f1376377448e8ad63f0663b0e3bae schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
123 schema:name Adult
124 rdf:type schema:DefinedTerm
125 N0361341f98794be9ab080a5372ceffcc schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
126 schema:name Arthritis, Rheumatoid
127 rdf:type schema:DefinedTerm
128 N03fccb4a26194ebfa332831796fa6c55 schema:issueNumber 1
129 rdf:type schema:PublicationIssue
130 N04a20bf21597425c9e643ae17df65f32 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
131 schema:name Double-Blind Method
132 rdf:type schema:DefinedTerm
133 N0c3ab250df324962a0f08861cc83c299 schema:name dimensions_id
134 schema:value pub.1011836710
135 rdf:type schema:PropertyValue
136 N0c3e46b75034427792556153e364e415 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
137 schema:name Blood Sedimentation
138 rdf:type schema:DefinedTerm
139 N109fe8fb05c741c3b41f972e8a1c2385 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
140 schema:name Piperidines
141 rdf:type schema:DefinedTerm
142 N191861c971ad49dcb7e3378671858b4e schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
143 schema:name Methotrexate
144 rdf:type schema:DefinedTerm
145 N1b71cecea18643e9830a445e9ac6e48c schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
146 schema:name Treatment Outcome
147 rdf:type schema:DefinedTerm
148 N287502c6477649229651b27097ff3e6c schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
149 schema:name Humans
150 rdf:type schema:DefinedTerm
151 N2a35815b401f4b1eb0c39e34b5e45b6d rdf:first sg:person.011262137261.94
152 rdf:rest Nf10d9c1beefd4bc6a6c9d757bc4fc3d1
153 N33bda90afd984c34a49338caa95a2bd1 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
154 schema:name Regression Analysis
155 rdf:type schema:DefinedTerm
156 N5016ff5dbf05468e88a9abca25a6957b rdf:first sg:person.01323573350.82
157 rdf:rest N88bfdba932134355a73a2be741815fb6
158 N5a4002d88e994290afbd57ab870b2a49 rdf:first sg:person.01065106031.43
159 rdf:rest N78840a44cb6143a780b860b171297a6b
160 N670bd777d8b746b89a54e6ebeed23b5e rdf:first sg:person.014133305773.18
161 rdf:rest N5016ff5dbf05468e88a9abca25a6957b
162 N6e1425078cea4ad38b9d07b10175374c schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
163 schema:name Drug Therapy, Combination
164 rdf:type schema:DefinedTerm
165 N6ee1973da3a84ea898fd3d5102848a36 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
166 schema:name Pyrroles
167 rdf:type schema:DefinedTerm
168 N78840a44cb6143a780b860b171297a6b rdf:first sg:person.012234527537.40
169 rdf:rest N670bd777d8b746b89a54e6ebeed23b5e
170 N7fa0c1777cff4c0f86d1368a416c4f6c schema:name doi
171 schema:value 10.1007/s10067-016-3436-1
172 rdf:type schema:PropertyValue
173 N82d0739072f449aba60a148f9d8b63ca schema:name pubmed_id
174 schema:value 27734232
175 rdf:type schema:PropertyValue
176 N85ae6e5156ca4d8686cb1b96f594dcb0 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
177 schema:name Pyrimidines
178 rdf:type schema:DefinedTerm
179 N88bfdba932134355a73a2be741815fb6 rdf:first sg:person.01011713026.12
180 rdf:rest Nba989ea6e2bd4171b786715be97a7b3b
181 N9563d2922fca44529f0ceca9ecf2443b schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
182 schema:name Antirheumatic Agents
183 rdf:type schema:DefinedTerm
184 N96e0aa0d03134a0d988bfa63615f994b schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
185 schema:name Male
186 rdf:type schema:DefinedTerm
187 Na15b73d881774506a68235bf5a3c4482 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
188 schema:name Disease Progression
189 rdf:type schema:DefinedTerm
190 Nb0c3f4e4a769407eb77279e526e7077e schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
191 schema:name Middle Aged
192 rdf:type schema:DefinedTerm
193 Nb5034f1a75f242f8b7440188431cb8e2 schema:volumeNumber 36
194 rdf:type schema:PublicationVolume
195 Nba989ea6e2bd4171b786715be97a7b3b rdf:first sg:person.0614545245.28
196 rdf:rest N2a35815b401f4b1eb0c39e34b5e45b6d
197 Ne5aa1ba4429749b2aafedd02f22eee94 schema:name Springer Nature - SN SciGraph project
198 rdf:type schema:Organization
199 Ne73abf2a84724c98b45207b3a5b264d1 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
200 schema:name Janus Kinases
201 rdf:type schema:DefinedTerm
202 Nf10d9c1beefd4bc6a6c9d757bc4fc3d1 rdf:first sg:person.01073167753.60
203 rdf:rest rdf:nil
204 Nf2c21df31075445da9eeedc91c37417a schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
205 schema:name Female
206 rdf:type schema:DefinedTerm
207 Nf8f630ccdfbe4ccab5ca605dd80984e1 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
208 schema:name Aged
209 rdf:type schema:DefinedTerm
210 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
211 schema:name Medical and Health Sciences
212 rdf:type schema:DefinedTerm
213 anzsrc-for:1103 schema:inDefinedTermSet anzsrc-for:
214 schema:name Clinical Sciences
215 rdf:type schema:DefinedTerm
216 sg:journal.1093299 schema:issn 0770-3198
217 1434-9949
218 schema:name Clinical Rheumatology
219 schema:publisher Springer Nature
220 rdf:type schema:Periodical
221 sg:person.01011713026.12 schema:affiliation grid-institutes:grid.410513.2
222 schema:familyName Soma
223 schema:givenName K
224 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01011713026.12
225 rdf:type schema:Person
226 sg:person.01065106031.43 schema:affiliation grid-institutes:grid.267313.2
227 schema:familyName Fleischmann
228 schema:givenName R
229 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01065106031.43
230 rdf:type schema:Person
231 sg:person.01073167753.60 schema:affiliation grid-institutes:grid.410513.2
232 schema:familyName Bananis
233 schema:givenName E
234 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01073167753.60
235 rdf:type schema:Person
236 sg:person.011262137261.94 schema:affiliation grid-institutes:grid.410513.2
237 schema:familyName Takiya
238 schema:givenName L
239 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.011262137261.94
240 rdf:type schema:Person
241 sg:person.012234527537.40 schema:affiliation grid-institutes:grid.34477.33
242 schema:familyName Mease
243 schema:givenName P J
244 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.012234527537.40
245 rdf:type schema:Person
246 sg:person.01323573350.82 schema:affiliation grid-institutes:grid.410513.2
247 schema:familyName Hwang
248 schema:givenName L-J
249 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01323573350.82
250 rdf:type schema:Person
251 sg:person.014133305773.18 schema:affiliation grid-institutes:grid.239915.5
252 schema:familyName Schwartzman
253 schema:givenName S
254 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.014133305773.18
255 rdf:type schema:Person
256 sg:person.0614545245.28 schema:affiliation grid-institutes:grid.410513.2
257 schema:familyName Connell
258 schema:givenName C A
259 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0614545245.28
260 rdf:type schema:Person
261 grid-institutes:grid.239915.5 schema:alternateName Hospital for Special Surgery, New York, NY, USA.
262 schema:name Hospital for Special Surgery, New York, NY, USA.
263 rdf:type schema:Organization
264 grid-institutes:grid.267313.2 schema:alternateName Metroplex Clinical Research Center and University of Texas Southwestern Medical Center, Dallas, TX, USA.
265 schema:name Metroplex Clinical Research Center and University of Texas Southwestern Medical Center, Dallas, TX, USA.
266 rdf:type schema:Organization
267 grid-institutes:grid.34477.33 schema:alternateName Swedish Medical Center and University of Washington School of Medicine, Seattle, WA, USA.
268 schema:name Swedish Medical Center and University of Washington School of Medicine, Seattle, WA, USA.
269 rdf:type schema:Organization
270 grid-institutes:grid.410513.2 schema:alternateName Pfizer Inc, Collegeville, PA, USA.
271 Pfizer Inc, Collegeville, PA, USA. stratis.bananis@pfizer.com.
272 Pfizer Inc, Groton, CT, USA.
273 Pfizer Inc, New York, NY, USA.
274 schema:name Pfizer Inc, Collegeville, PA, USA.
275 Pfizer Inc, Collegeville, PA, USA. stratis.bananis@pfizer.com.
276 Pfizer Inc, Groton, CT, USA.
277 Pfizer Inc, New York, NY, USA.
278 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...